Hormonal
Discontinuation of GLP-1 RA treatment leads to significant weight regain (up to 68% of lost weight) and reversal of cardiometabolic improvements, indicating that obesity requires chronic management.
If you stop taking GLP-1 medications, you will likely regain most of the weight you lost, along with your previous metabolic risks. This is because obesity is a chronic condition, not a temporary state. Just as you wouldn't stop blood pressure medication, you likely need to stay on GLP-1 therapy long-term to maintain your weight loss. The goal is sustained health, not a short-term fix.
In an extension of the STEP-1 trial, participants originally randomized to semaglutide regained 68% of their lost weight after one year of discontinuing treatment... Cardiometabolic improvements achieved with semaglutide also reverted towards baseline for most risk factors after one year.
Why this rating
Based on STEP-1 and STEP-4 trial extensions.
Source
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
Areesha Moiz et al. · EClinicalMedicine · 2025
DOI 10.1016/j.eclinm.2025.103363
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) produce clinically meaningful weight loss of 15–20% in clinical trials, significantly exceeding the modest 3–9% loss from alternative pharmacotherapies and the partial regain seen with lifestyle interventions alone.Strong
- GLP-1 receptor agonists provide significant cardiorenal protection, reducing major adverse cardiovascular events (MACE) and kidney-related complications in patients with type 2 diabetes and/or cardiovascular disease, independent of weight loss.Strong
- GLP-1 receptor agonists are associated with a modestly increased risk of gallbladder and biliary disorders, particularly at higher doses and longer treatment durations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →